PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Gauges a company's financial stability and solvency. Value investors pay close attention to leverage and liquidity risk, ensuring the company has enough cushion to withstand downturns without impairing shareholder value.
0.06
D/E ratio near Drug Manufacturers - Specialty & Generic median of 0.06. Philip Fisher would examine if industry-standard leverage is optimal for the business model.
-60.42
Net cash position versus Drug Manufacturers - Specialty & Generic median net debt of 0.85. Peter Lynch would praise the flexibility but check if overcapitalized versus growth opportunities.
5.10
Coverage of 5.10 versus zero Drug Manufacturers - Specialty & Generic median interest expense. Walter Schloss would verify if our leverage provides advantages.
27.25
Current ratio exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 2.69. Joel Greenblatt would verify if this conservative approach provides competitive advantages.
5.00%
Intangibles 50-90% of Drug Manufacturers - Specialty & Generic median of 7.14%. Charlie Munger would examine if industry dynamics justify more tangible-heavy model.